New report shows record 235 number of diabetes drugs currently in development in USA

26 May 2010

A record 235 new medicines to treat diabetes, one of the fastest-growing diseases in America, are being developed by the USA's pharmaceutical and biotechnology companies, according to a national report unveiled this week in Charleston, West Virginia, which has the highest rate of diabetes in the country.

In West Virginia, 11.4% of the adult population suffers from diabetes - a rate that has more than doubled since 1994, according to a Centers for Disease Control and Prevention study of data from 2006-2008.

The alarming rates of diabetes are being seen throughout the nation, said Ken Johnson, senior vice president of the Pharmaceutical Research and Manufacturers of America (PhRMA) on announcing the report, and saying: "Perhaps the most shocking and disturbing trend is the rise of diabetes among children, which the American Diabetes Association calls 'a new epidemic.'"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology